N-Acetyl-L-Cysteine
Liver Failure
Azienda Ospedaliera di PadovaPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
6 Active assets in the Liver Failure cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Empagliflozin Yale University | Phase 4 | BB |
Avatrombopag Tongji Hospital | Phase 4 | BB |
Erythropoietin Human Recombinant Institute of Liver and Biliary Sciences, India | Phase 3 | BB |
Pentoxifylline Assistance Publique - Hôpitaux de Paris | Phase 3 | BB |
SODIUM TETRADECYL SULFATE Kaohsiung Veterans General Hospital. | Phase 3 | B |
View all 24 →
Same molecule, other indications
N-Acetyl-L-Cysteine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →